Associated Papers
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries.
Das Ghosh D et al.
Gynecologic Oncology Reports, 2023
37293351 (PubMed )
Supplement: mmc2.xlsx › TP53
An update on the central nervous system manifestations of Li-Fraumeni syndrome.
Orr BA et al.
Acta Neuropathologica, 2020
From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion.
Quinn EA et al.
Cold Spring Harbor Molecular Case Studies, 2019
30886117 (PubMed )
Supplement: supp_mcs.a003921_Supplemental_Table_2.xlsx › S_Table2._IARC_Database__R19
Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH et al.
Oncotarget, 2016
27528217 (PubMed )
Supplement: oncotarget-07-61575-s001.pdf
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nik-Zainal S et al.
Nature, 2016
27135926 (PubMed )
Supplement: NIHMS68344-supplement-Supplementary_Tables_1-21.zip › nature17676-s3 › Supplementary_Table_14.Driver.Events.By.Mutation.Type.01052015.v2.xlsx › Subs.indels
Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components.
Actor B et al.
Genes, Chromosomes & Cancer, 2002
Select a paper to view details